Trial Profile
Randomized Conversion of Calcinurin-Inhibitors (Tacrolimus to Sirolimus) at 6-24 Months Post Transplant in a Prednisone-Free Immunosuppression Regimen: Impact of Incidence of Acute Cellular Rejection, Renal Allograft Function and T Cell Function
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Mycophenolate mofetil; Tacrolimus
- Indications Renal transplant rejection
- Focus Pharmacodynamics; Therapeutic Use
- 08 May 2019 Status changed from active, no longer recruiting to completed.
- 18 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 18 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.